Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01782209 · ClinicalTrials.gov registry record
BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 335
- Enrollment target
NCT01782209: Completed study, sponsored by University of Alabama at Birmingham.
NCT01782209 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 335 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01782209 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 335 participants
- Enrollment target
Study Summary
The objectives of this study is to establish the natural history of BK virus viremia and other possible opportunistic viral pathogens in renal transplants recipients.
Primary Outcome
We will measure the number of subjects screened who develops BK viremia within 4 weeks and up to 24 months after renal transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2014-06 |
| Est. Completion | 2019-12 |
What the finished NCT01782209 record still lists
NCT01782209 is an observational study that tracks outcomes without assigning an intervention. The registered 335 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01782209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01782209 about?
NCT01782209 is a clinical study titled "BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients". The objectives of this study is to establish the natural history of BK virus viremia and other possible opportunistic viral pathogens in renal transplants recipients.
What is the current status of trial NCT01782209?
This trial is currently completed. The enrollment target is 335 participants. The study started on 2014-06. Estimated completion is 2019-12.
Who is sponsoring clinical trial NCT01782209?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134754 · 335 participants · NA
Carbon Dioxide (CO2) Chemosensitivity and SUDEP
- NCT05554406 · 335 participants · Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT06183437 · 335 participants · Phase 4
The STOP-MED CTRCD Trial
- NCT06885177 · 335 participants · NA
TECTONIC CAD IVL IDE Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia